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AbstrAct
Objectives In stable coronary artery disease (CAD), 
coronary revascularisation may reduce mortality 
of patients with a certain amount of left ventricular 
myocardial ischaemia. However, revascularisation does 
not always follow the guidance suggested by ischaemia 
testing. We compared outcomes in patients without 
ischaemia who had either revascularisation or medical 
treatment.
Design and population Based on registries, 1327 
consecutive patients with normal myocardial perfusion 
scintigraphy (MPS) and 278 with fixed perfusion defects 
were followed for a median of 6.1 years. Most patients 
received medical therapy alone (Med), but 26 (2%) with 
a normal MPS and 15 (5%) with fixed perfusion defects 
underwent revascularisation (Revasc).
Outcome measures Incidence rates of all-cause death 
(ACD) and rates of cardiac death/myocardial infarction 
(CD/MI).
results With a normal MPS, the ACD rate was 6.2%/year 
in the Revasc group versus 1.9%/year in the Med group 
(p=0.01); the CD/MI rates were 6.9%/year and 0.6%/
year, respectively (p<0.00001). Results persisted after 
adjustment for predictors of revascularisation, in particular 
angina score, and in comparisons of matched Revasc and 
Med patients. With fixed defects, the ACD rate was 9.1%/
year in the Revasc group and 6.7%/year in the Med group 
(p=0.44); the CD/MI rate was 5.0%/year versus 4.2%/
year, respectively (p=0.69). If adjusted for angiographic 
variables or analysed in matched subsets, differences 
remained insignificant.
conclusions With normal MPS, revascularisation 
conferred a higher risk, even after adjustment for 
predictors of revascularisation. With fixed defects, the 
Revascversus Med difference was close to equipoise. 
Hence, in patients with stable CAD without ischaemia, 
we could not find evidence to justify exceptional 
revascularisation.
IntrODuctIOn
In stable angina pectoris patients at low to 
intermediate risk of coronary artery disease 
(CAD), it is recommended to use non-invasive 
testing as a gatekeeper to coronary angiog-
raphy.1 2 Myocardial perfusion scintigraphy 
(MPS) is an ischaemia test that effectively 
stratifies patients with an intermediate pre-test 
risk into groups with low or high post-test risk 
and, hence, identifies potential candidates 
for coronary revascularisation.3–5 Revascular-
isation is often performed with the intention 
to improve symptoms or prognosis; however, 
a survival benefit over optimal medical 
therapy has not been documented in patients 
with stable CAD.6–8 Data from registry-based 
studies suggest that only in the presence of a 
certain amount of ischaemia is the prognosis 
with respect to hard events better with coro-
nary revascularisation than with conservative 
therapy.9 10 Nevertheless, in daily routine a 
small proportion of patients with normal MPS 
or fixed defects still undergoes revascularisa-
tion. It remains an open question whether this 
reflects a clinically justified exception to the 
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Research
strengths and limitations of this study
 ► The observational design gave a rare chance to 
study outcome in a clinical setting, where myocardial 
perfusion scintigraphy  (MPS) results were open to 
referring clinicians.
 ► Endpoints were collected from comprehensive 
national registries ensuring a high validity.
 ► Rationales for the choice of post-MPS treatment 
were found in medical records, which may have 
reduced the ability to address explanatory factors.
 ► The major limitation was the small number of 
patients undergoing revascularisation (n=41).
 ► However, careful adjustment was undertaken in 
order to achieve a fair comparison of subgroups, and 
a matching approach was also used.
 ► We focused on hard events, which are indisputable. 
On the other side, we cannot tell from the present 
material whether revascularisation yielded an 
amelioration of symptoms.
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regular practice. Addressing this question is a non-trivial 
task as a potential inferior prognosis in the revascularised 
patients may simply reflect a proper clinical selection of 
high-risk patients with a real need for revascularisation, 
regardless of the MPS result. Comparison of patients 
with similar risk profiles as regards potential prognostic 
factors related to the treatment decision might allow for 
an answer. In an observational design, we compared the 
outcome with and without coronary revascularisation in 
consecutive patients with symptoms of stable CAD but 
without ischaemia in a setting, where the MPS results 
were open to the treating physicians.
MAterIAls AnD MethODs
Study population and design
From a consecutive series of 2157 MPS performed 
2002–2007 at Odense University Hospital for suspected 
or known CAD in patients who did not participate in a 
research project, 1327 patients had normal scintigraphic 
findings while 278 demonstrated fixed perfusion defects. 
Results were analysed for all patients and for subsets 
undergoing early revascularisation (Revasc) or receiving 
pure medical therapy (Med). Early revascularisation was 
defined as percutaneous coronary intervention (PCI) or 
coronary artery bypass grafting (CABG) within 180 days 
from MPS, while performed >180 days later was termed 
late revascularisation. Trial design and methods were 
published previously.11 The study was approved by the 
local data protection committee.
MyOcArDIAl perfusIOn scIntIgrAphy
MPS was performed as single photon emission CT with 
technetium-99m sestamibi using a standard maximum 
exercise test or pharmacological stress by adenosine, 
dipyridamole or dobutamine. In the early study period, 
non-gated acquisitions were used. Later, gated studies 
were used with at-rest left ventricular ejection fraction 
(LVEF) being available in 648 patients (49%) with normal 
MPS and 147 patients (53%) with fixed defects. For 
post-stress LVEF, the numbers were 687 (52%) and 123 
(44%), respectively. Scans were interpreted semiquantita-
tively and deemed normal in case of normal radionuclide 
distribution throughout the myocardium in the presence 
also of normalcy with respect to available non-perfu-
sion markers like wall thickening/motion, ventricular 
size and LVEF. All abnormal scans were reviewed by an 
experienced reader (AJ) blinded to clinical data. Extent 
and severity of perfusion defects at stress imaging were 
converted to percentage myocardium and categorised 
as small (5%–9% of the myocardium), moderate (10%–
14%) or large (>14%).12
follow-up
History of CAD and medication at the time of MPS 
were retrieved from medical records and MPS reports. 
Follow-up ran from the date of the MPS until 31 
December 2011. Events during follow-up were appointed 
by means of regional and national registers as previously 
described.11 Medical records were examined for treatment 
decision, and angiographic data were obtained from the 
Western Denmark Heart Registry comprising records on 
all coronary angiographies and revascularisation proce-
dures performed in Western Denmark, including angina 
score according to the Canadian Cardiovascular Society 
(CCS).13
statistics
Continuous and categorical variables are shown by means 
of descriptive statistics and frequency counts including 
percentages, respectively. Intergroup differences in 
continuous variables were tested by the Wilcoxon 
rank-sum test; frequencies were compared by Fisher’s 
exact test or the χ2 test. Main endpoints were all-cause 
death (ACD) and cardiac death (defined as death from 
ischaemic heart disease, congestive heart failure or malig-
nant arrhythmia) or non-fatal myocardial infarction (CD/
MI). Time until event is illustrated with cumulative inci-
dence functions. Cause-specific HRs (CSHRs) based on 
a Cox proportional hazard model as well as subdistribu-
tion HRs (SDHRs) based on the Fine and Gray regression 
model14 were used to assess the difference between Revasc 
and Med. The HRs were adjusted for main predictors of 
revascularisation, which were identified by comparison of 
the two treatment groups and an analysis of the reasons 
given in the medical records of revascularised patients. 
Adjustment was performed for one covariate at a time as 
well as in multivariate models. When considering ACD, 
late revascularisation was regarded as a competing event 
in order not to bias the natural course. When considering 
CD/MI, non-cardiac death and late revascularisation were 
regarded as competing events. Following the general 
advice to consider all competing events in the statistical 
analysis,15 16 we present cumulative incidence functions 
for all four events but restrict reporting of HRs to the two 
main endpoints.
Furthermore, a matching approach was used. For each 
revascularised patient, we found a medically treated match 
with identical or nearly identical values for the variables 
predictive of revascularisation. Event incidences for the 
revascularised patients and their matches were compared 
by cumulative incidence curves, CSHRs and SDHRs.
The significance level was set to 5%. Statistical anal-
yses were performed with STATA v.12. Matching was 
performed with the ‘optmatch’ program17 and incidence 
rates were compared with the ‘stir’ command.
results
Early revascularisation was performed in 26 patients (2%) 
with normal MPS and in 15 patients (5%) with fixed 
defects. Characteristics are given in table 1.
The decision to revascularise was clearly associated 
with symptoms and angiographic findings but less with 
MPS results (table 2). In four cases of normal MPS, 
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Table 1 Patient characteristics
All Revascularisation Medical therapy p Value
(a) Patients with normal MPS
N 1327 26 1301
Age, years (mean±SD) 59.5±11.8 62.1±12.2 59.5±11.8 0.29
Male 574 (43) 17 (65) 557 (43) 0.03
Known CAD 248 (19) 15 (58) 233 (18) <0.0001
History
  MI 87 (7) 6 (23) 81 (6) 0.005
  PCI 149 (11) 12 (46) 137 (11) <0.0001
  CABG 59 (4) 2 (8) 57 (4) 0.32
Diabetes mellitus 202 (15) 5 (19) 197 (15) 0.58
Medication
  Aspirin 797 (60) 23 (88) 774 (59) 0.001
  Beta blocker 462 (35) 20 (77) 442 (34) <0.0001
  Calcium channel blocker 325 (24) 9 (35) 316 (24) 0.25
  Nitrates 279 (21) 8 (31) 271 (21) 0.23
  Lipid-lowering agents 481 (36) 16 (62) 465 (36) 0.01
LVEF, rest, N 648 15 633 1.00
  <30% 0 0 0
  30≤ LVEF<50% 34 (5) 0 34 (5)
  ≥50% 614 (95) 15 (100) 599 (95)
LVEF, stress, N 687 16 671 0.63
  <30% 0 0 0
  30≤ LVEF<50% 41 (6) 0 41 (6)
  ≥50% 646 (94) 16 (100) 630 (94)
Family history of CAD, N 216 23 193 0.83
  Positive 113 (52) 13 (57) 100 (52)
CCS score, N 223 26 197 0.01
  1 122 (55) 10 (38) 112 (57)
  2 76 (34) 8 (31) 68 (35)
  3 24 (11) 8 (31) 16 (8)
  4 1 (0.4) 0 1 (0.5)
Smoking, N 203 22 181 0.41
  Current 56 (28) 8 (36) 48 (27)
  Never 79 (39) 6 (27) 73 (40)
  Ceased 68 (34) 8 (36) 60 (33)
Stenotic vessels, N 210 26 184 <0.0001
  0 101 (48) 2 (8) 99 (54)
  1 59 (28) 10 (38) 49 (27)
  2 30 (14) 7 (27) 23 (13)
  3 20 (10) 7 (27) 13 (7)
(b) Patients with fixed perfusion defects
N 278 15 263
Age, years (mean±SD) 62.5±10.2 61.6±11.5 62.6±10.1 0.63
Male 214 (77) 14 (93) 200 (76) 0.20
Known CAD 196 (71) 11 (73) 185 (70) 1.00
Continued
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(b) Patients with fixed perfusion defects
History
  MI 152 (55) 8 (53) 144 (55) 1.00
  PCI 101 (36) 6 (40) 95 (36) 0.79
  CABG 76 (27) 3 (20) 73 (28) 0.77
Diabetes mellitus 59 (21) 5 (33) 54 (21) 0.33
Medication
  Aspirin 233 (84) 12 (80) 221 (84) 0.72
  Beta blocker 177 (64) 9 (60) 168 (64) 0.79
  Calcium channel blocker 76 (27) 6 (40) 70 (27) 0.25
  Nitrates 75 (27) 4 (27) 71 (27) 1.00
  Lipid-lowering agents 169 (61) 8 (53) 161 (61) 0.59
Size of defects 0.62
  Small (5%–9%) 92 (33) 4 (27) 88 (33)
  Medium (10%–14%) 60 (22) 2 (13) 58 (22)
  Large (>14%) 126 (45) 9 (60) 117 (45)
LVEF, rest, N 147 4 143 0.79
  <30% 20 (14) 0 20 (14)
  30≤LVEF<50% 57 (39) 1 (25) 56 (39)
  ≥50% 70 (48) 3 (75) 67 (47)
LVEF, stress, N 123 5 118 0.84
  <30% 21 (17) 0 21 (18)
  30≤LVEF<50% 48 (39) 2 (40) 46 (39)
  ≥50% 54 (44) 3 (60) 51 (43)
Family history of CAD, N 106 14 92 0.77
  Positive 45 (42) 5 (36) 40 (43)
CCS score, N 115 15 100 0.13
  1 73 (63) 7 (47) 66 (66)
  2 25 (22) 3 (20) 22 (22)
  3 16 (14) 5 (33) 11 (11)
  4 1 (1) 0 1 (1)
Smoking, N 102 13 89 1.00
  Current 36 (35) 5 (38) 31 (35)
  Never 19 (19) 2 (15) 17 (19)
  Ceased 47 (46) 6 (46) 41 (46)
Stenotic vessels, N 108 15 93 0.002
  0 15 (14) 0 15 (16)
  1 26 (24) 3 (20) 23 (25)
  2 34 (31) 11 (73) 23 (25)
  3 33 (31) 1 (7) 32 (34)
CAD, coronary artery disease; CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; MPS, myocardial perfusion scintigraphy; PCI, percutaneous coronary intervention.
Table 1 Continued 
revascularisation was performed following a new incident 
independent of the symptoms prompting MPS.
Median follow-up (range) was 6.1 years (0.02–9.96). 
Table 3 shows the cumulative numbers of events during 
follow-up. With normal MPS, the number of MIs was 
higher than the number of CDs (3% vs 1%, p<0.0001), 
whereas in the patients with fixed defects, the disparity, 
although insignificant, was the reverse (10% vs 14%, 
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p=0.19). In none of the MPS groups did the CD/ACD 
ratio differ between subgroups; being 2/7 and 14/150, 
respectively (p=0.15) in normal MPS and 3/7 versus 
35/88 (p=1.00) in patients with fixed defects (table 3).
Cumulative incidence functions shown in figure 1 
indicated no difference in the incidence of non-cardiac 
deaths between the two treatment groups for neither 
patients with normal MPS, nor patients with fixed defects. 
As regards late revascularisation, the Med curve tended 
to run above the Revasc curve in case of fixed defects; 
however, the difference was not significant. With normal 
MPS, substantially different incidence rates of the main 
endpoints could be observed. The ACD rate was 6.2%/
year in the Revasc group compared with 1.9%/year in 
the Med group (p=0.01) and the CD/MI rate was 6.9%/
year versus 0.6%/year, respectively (p<0.00001). In case 
of fixed defects, there were no significant intergroup 
differences, and Revasc/Med ratios were similar for both 
endpoints: the ACD rate was 9.1%/year in the Revasc 
group and 6.7%/year in the Med group (p=0.44) and the 
CD/MI rate was 5.0%/year versus 4.2%/year, respectively 
(p=0.69).
Quantification of effects and adjustment
Judged from tables 1 and 2, variables CAD, previous MI, 
previous PCI, CCS score and number of stenotic coronary 
arteries were associated with the decision to revascularise 
despite normal MPS. The use of aspirin, beta blockers 
and lipid-lowering agents was unequally distributed 
and, hence, could be a surrogate for a disease state also 
predictive of revascularisation. Gender was also unevenly 
distributed and, therefore, considered in the models. In 
patients with fixed effects, the only significant association 
found was for the number of stenotic arteries. The lack of 
significance for the other variables may, however, mainly 
reflect lack of power due to the small number of revas-
cularised patients. It seems reasonable to assume that 
variables predictive of the treatment decision in patients 
with normal MPS would also be potential predictors in 
patients with fixed effects. Hence, we used the same list of 
(potential) predictors.
Unadjusted and adjusted CSHRs and SDHRs comparing 
the Revasc and Med groups are shown in table 4. Adjust-
ment for clinical and/or angiographic variables did not 
change the HRs with normal MPS, which were always 
in the magnitude of 3–5 for ACD and >9 for CD/MI, all 
being significantly different from 1. With fixed defects, 
the HR was never significantly different from 1. Adjusted 
for clinical variables, the HRs for both outcomes stayed 
in the magnitude of 1.2–1.8. However, with adjustment 
for angiographic variables the HR changed more substan-
tially to values around 2 for ACD and between 0.7 and 0.9 
for CD/MI.
Scintigraphic variables, available only in a subgroup 
of all patients, were also to some degree associated with 
treatment decisions. All the Revasc patients with normal 
MPS had LVEF≥50%, whereas some of the Med patients 
had 30≤LVEF<50% (table 1a). Adjustment for LVEF 
category slightly reduced the HRs for ACD but not for 
CD/MI (table 4a). One out of four of the Revasc patients 
with fixed defects had a moderately reduced at-rest LVEF 
(30≤LVEF<50%), but no one had a severely reduced LVEF 
(<30%), which was the case in 14% of the Med patients 
(table 1b). Adjustment for LVEF category reduced the 
HRs for ACD, whereas for CD/MI, numbers were too 
small for an estimation. Similarly, in spite of no signifi-
cant intergroup difference in size of perfusion defects, 
adjustment for defect size slightly reduced the HR for 
both endpoints (table 4b).
Results from the matching procedure can be seen from 
the online supplementary material. For matched subsets, 
results were similar to those from the entire groups; in 
case of normal MPS, the CSHR was 7.97 (p=0.05) for ACD, 
4.12 (p=0.08) for CD/MI. With fixed defects, the CSHR 
was 1.00 (p=1.00) for ACD and 0.70 (p=0.67) for CD/MI, 
respectively. Cumulative incidence functions resembled 
those for the entire groups. Detailed results are given in 
the online supplementary table and online supplemen-
tary figure.
DIscussIOn
In this study, 2% of patients with normal MPS and 5% with 
fixed perfusion defects underwent early coronary revas-
cularisation; that is, exceptional revascularisation. With 
normal MPS, Revasc patients had significantly higher 
event rates than Med patients. With fixed defects, no 
significant intergroup differences were observed. Results 
persisted after adjustment for predictors of revascular-
isation as well as after matching. Noteworthy, MPS was 
conducted as a part of the routine diagnostic work-up and 
results were open to the referring clinicians. Still, revas-
cularisation was undertaken in some patients, probably 
primarily based on angiographic and clinical findings.
use of Mps
In patients with stable angina, an ischaemia test is far from 
always performed before angiography.18 19 An anatomical 
approach to the CAD diagnosis and quantification typi-
cally leads to more revascularisation procedures than a 
functional approach.20–22 However, strategies involving 
MPS have a greater prognostic power than those without 
functional testing.23 24
Optimal risk stratification derives from the ability of a 
normal MPS to identify patients at exceedingly low risk, 
and that of an abnormal scan to identify patients at greater 
risk, thus rendering a number of catheterisation and inva-
sive interventions superfluous.25–27 Following a normal 
MPS, the annual death rate is generally <2% and the 
annual rate of hard cardiac events<1%, a little higher in 
risk groups.28 29 We and others previously found a general 
warranty period following a normal MPS of 5 years11.30 
Thus, under usual conditions, cardiac catheterisation is 
not warranted in the presence of a normal study, unless 
there is a change in symptoms.
 9Simonsen JA, et al. BMJ Open 2017;7:e016169. doi:10.1136/bmjopen-2017-016169
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Figure 1 Cumulative incidence functions. Blue lines: revascularisation; red lines: medical therapy. (a) Patients with normal 
myocardial perfusion scintigraphy; (b) patients with fixed perfusion defects. ACD, all-cause death; CD, cardiac death; MI, 
myocardial infarction.
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A small percentage of patients with normal scans do 
have events within the warranty period. In our popula-
tion of 1327 patients with normal MPS, 4 patients (0.3%) 
underwent revascularisation within 6 months from MPS 
because of an acute MI. One had diabetes, one had 
chronic kidney disease and two had known CAD. This 
supports previous findings of a poorer prognosis for 
high-risk subgroups and underscores the additional prog-
nostic value of clinical findings to MPS results. It also 
illustrates the fact that MI—more than death—is hard to 
anticipate.31 MIs can break out in vessels with a normal 
appearance,32 33 whereas stenotic and occluded arteries 
often come with collaterals, preventing MI or at least 
limiting its size.34 Hence, although the occurrence of MI 
is associated with the presence of atherosclerosis, it may 
not be correlated to its severity, and therefore, MPS—
like other imaging techniques—cannot predict specific 
lesions but patients at risk.35 36
The risk of false negative MPS results caused by 
balanced ischaemia was reduced as non-perfusion scan 
markers were also taken into consideration. LV function 
in the shape of LVEF has an independent prognostic and 
predictive value.3 10 However, decision to perform revas-
cularisation in our patients was in general not based on 
the presence of a reduced LVEF as all Revasc patients 
with normal MPS had preserved LVEFs, and far from all 
patients with an LVEF <50% underwent revascularisation.
Dominant MPS parameters driving subsequent resource 
utilisation are extent and severity of reversible perfusion 
defects.12 In addition, a variety of clinical elements, most 
importantly anginal symptoms, further influence referral 
rates.20 Thus, when patients with normal scans or scans 
showing only mild ischaemia are referred to angiography, 
this is typically based on clinical symptoms.37 In former 
reports from the USA, 3% of patients without ischaemia 
were referred to angiography, and revascularisation was 
performed in one-fifth of these.38–40 The numbers in our 
series were higher.
strengths and limitations
Contrary to previous reports on post-MPS assignment 
in which the authors were left to speculate on possible 
reasons for paradoxical treatments,20 we went through 
medical records describing rationales for the choice of 
treatment, well aware that it is difficult to find specific 
information on the reason for a clinical decision in 
retrospect. Careful adjustment was undertaken in order 
to achieve a fair comparison of subgroups. Due to a 
low number of revascularisations, PCI and CABG were 
looked at together. This may, however, be inappropriate 
as several studies have shown that CABG-treated patients 
have a lower MI rate compared with PCI-treated patients.
Subsets treated exceptionally, given the MPS findings, 
constituted a minority of our patients. Considering the 
small number of Revasc patients compared with Med 
patients, it was not equitable to estimate a propensity 
score. However, results from Cox models adjusted for 
individual covariates are comparable to results from 
propensity score-adjusted Cox models.41 Adjustment for 
different predictors of revascularisation did not change 
our results; specifically, differences persisted after 
adjustment for angina score, one of the most important 
predictors of revascularisation. In addition, results of the 
matching approach were comparable to those from Cox 
modelling, that is, effects observed in univariate analyses 
did not vanish. An indicator of an even distribution of 
non-cardiac health problems affecting prognosis as well 
as treatment decision was the fact that in none of the 
subgroups of our patients did we observe a significant 
difference between the CD/ACD ratios.
In analysing outcome, we focused on hard events. Just 
like observational studies have indicated that at least 10% 
of the LV myocardium should be ischaemic in order 
for the patient to gain a survival benefit,42–44 the same 
amount seems to be a prerequisite of an improvement in 
symptoms and exercise capacity.45 46 Hence, revascularisa-
tion is unlikely to benefit stable patients with CAD unless 
there is objective evidence of ischaemia.
cOnclusIOns
In our consecutive series of patients undergoing MPS for 
stable angina pectoris in the clinical routine, 2% of those 
with normal MPS and 5% of those with fixed perfusion 
defects underwent revascularisation against the guide-
lines. With normal MPS, Revasc was associated with 
significantly more cardiac events and shorter survival than 
Med, even after adjustment for clinical, angiographic and 
scintigraphic variables. With fixed defects, there were 
no significant differences. Thus, our findings could not 
justify deviations from the rule to avoid coronary revas-
cularisation in the absence of myocardial ischaemia in 
patients with stable angina pectoris .
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